



PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1642

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	Application Number	09/856,812-Conf. #3475
	Filing Date	September 7, 2001
	First Named Inventor	Lang-Qing Huang
	Art Unit	1642
	Examiner Name	M. T. B. Davis
	Attorney Docket Number	L0461.70115US00

### ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form PTO-1449; International Search Report for PCT/IB99/02018; References Cited; Check in the amount of \$180.00; Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
	<b>Remarks</b>	

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	John R. Van Amsterdam		
Date	July 9, 2007	Reg. No.	40,212

#### Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 9, 2007

Signature:

(Sylvana Householder)



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL

## For FY 2007

 Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** (\$ 180.00)
**Complete if Known**

Application Number	09/856,812-Conf. #3475
Filing Date	September 7, 2001
First Named Inventor	Lang-Qing Huang
Examiner Name	M. T. B. Davis
Art Unit	1642
Attorney Docket No.	L0461.70115US00

**METHOD OF PAYMENT** (check all that apply)

Check  Credit Card  Money Order  None  Other (please identify): \_\_\_\_\_  
 Deposit Account Deposit Account Number: 23/2825 Deposit Account Name: Wolf, Greenfield & Sacks, P.C.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below  Charge fee(s) indicated below, except for the filing fee  
 Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17  Credit any overpayments

**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES****Fee Description**

Fee Description	Small Entity Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 20 =	x	=	

<u>Multiple Dependent Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 3 =	x	=	

HP = highest number of independent claims paid for, if greater than 3.

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 100 =	/50 =	(round up to a whole number) x	=	

**4. OTHER FEE(S)**


Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

<b>SUBMITTED BY</b>			
Signature		Registration No. (Attorney/Agent)	40,212
Name (Print/Type)	John R. Van Amsterdam	Date	July 9, 2007

**Certificate of Mailing Under 37 CFR 1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 9, 2007Signature:  (Sylvana Householder)



DOCKET NO.: L0461.70115US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Lan-Qing Huang et al.  
Serial No.: 09/856,812  
Confirmation No.: 3475  
Filed: September 7, 2001  
For: TUMOUR REJECTION ANTIGENS

Examiner: Davis, Minh Tam B.  
Art Unit: 1642

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 9th day of July, 2007.

  
Sylvana Householder

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF**  
**DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

07/11/2007 EAYALEW1 00000028 09856612

01 FC:1806

180.00 0P

1211338.1

**PART II: Information Cited**

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

**International Search Report for International Application No. PCT/IB99/02018, mailed June 27, 2000.**

The following are remarks concerning the other information cited:

**PART III: Remarks**

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:

  
John R. Van Amsterdam, Ph.D.

Reg. No. 40,212

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: L0461.70115US00

Date: July 9, 2007

xNDDx



FOR PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet \_\_\_\_\_ of \_\_\_\_\_ GROUP ART UNIT: 1642 EXAMINER: Davis, Minh Tam B.

**U.S. PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/T.D./	A1	5,686,068	A	Boon-Falleur et al.	22-11-1997

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
/T.D./	B1	WO	98/14463	A	Ludwig Institute for Cancer Research	04-09-1998	
↓	B2	WO	95/25530	A	Ludwig Institute for Cancer Research; Univ Leiden	09-28-1995	
↓	B3	WO	99/54738	A	Ludwig Institute for Cancer Research	10-28-1999	
↓	B4	WO	99/61916	A	Epimmune, Inc.	12-02-1999	
↓	B5	WO	92/20356	A	Ludwig Institute for Cancer Research	11-26-1992	
↓	B6	WO	99/45954	A	Eppimmune, Inc.	09-16-1999	

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/T.D./	C1	CHEN, YAO-TSENG et al., "Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library," <i>Proc. Natl. Acad. Sci. USA</i> June 1998; 95:6919-6923.	
↓	C2	COULIE, P.G., "Antigens Recognized on Human Tumors by Cytolytic T Lymphocytes: Towards Vaccination?" <i>Stem Cells</i> 1995; 13(4):393-403.	
↓	C3	DABOVIC, B. et al., "A family of rapidly evolving genes from the sex reversal critical region in Xp21," <i>Mammalian Genome</i> 1995; 6:571-580.	
↓	C4	DE PLAEN, ETIENNE et al., "Structure, chromosomal localization, and expression of 12 genes of the MAGE family," <i>Immunogenetics</i> 1994; 40:360-369.	

EXAMINER:

/Minh Tam Davis/ (11/13/2007)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>			APPLICATION NO.: 09/856,812	ATTY. DOCKET NO.: L0461.70115US00	
			FILING DATE: September 7, 2001	CONFIRMATION NO.: 3475	
			APPLICANT: Lan-Qing Huang et al.		
			Sheet	of	GROUP ART UNIT: 1642

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/T.D./	C5	GAUGLER, BEATRICE et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes," <i>J. Exp. Med.</i> 1994; 179:921-930.	
	C6	GILBERT, SARAH C. et al., "A protein particle vaccine containing multiple malaria epitopes," <i>Nature Biotechnology</i> November 1997; 15:1280-1284.	
	C7	HAAS, GILBERT G. et al., "Distribution of Human Leukocyte Antigen-ABC and -D/DR Antigens in the Unfixed Human Testis," <i>American Journal of Reproductive Immunology and Microbiology</i> 1988; 18:47-51.	
	C8	HU, XUEYOU et al., "Enhancements of Cytolytic T Lymphocyte Precursor Frequency in Melanoma Patients following Immunization with the MAGE-1 Peptide Loaded Antigen Presenting Cell-based Vaccine," <i>Cancer Research</i> June 1, 1996; 56:2479-2483.	
	C9	HUANG, LAN-QING et al., "Cytolytic T Lymphocytes Recognize an Antigen Encoded by MAGE-A10 on a Human Melanoma," <i>The Journal of Immunology</i> 1999; 162:6849-6854.	
	C10	LUCAS, SOPHIE et al., "Identification of a New Mage Gene with Tumor-specific Expression by Representational Difference Analysis," <i>Cancer Research</i> February 15, 1998; 58:743-752.	
	C11	LURQUIN, CHRISTOPHE et al., "Two Members of the Human MAGEB Gene Family Located in Xp21.3 Are Expressed in Tumors of Various Histological Origins," <i>Genomics</i> 1997; 46:397-408.	
	C12	MARCHAND et al., "Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3," <i>Int. J. Cancer</i> 1995; 63:883-885.	
	C13	MUKHERJI, BIJAY et al., "Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells," <i>Proc. Natl. Acad. Sci. USA</i> August 1995; 92:8078-8082.	
	C14	MUSCATELLI, F. et al., "Isolation and characterization of a MAGE gene family in the Xp21.3 region," <i>Proc. Natl. Acad. Sci. USA</i> May 1995; 92:4987-4991.	
	C15	NESTLE, FRANK O. et al., "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," <i>Nature Medicine</i> March 1998; 4(3):328-332.	
	C16	RAMMENSEE, HANS-GEORG et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 1995; 41:178-228.	
▼	C17	RIMOLDI, DONATA et al., "cDNA and Protein Characterization of Human MAGE-10," <i>Int. J. Cancer</i> 1999; 82:901-907.	

EXAMINER: /Minh Tam Davis/ (11/13/2007)	DATE CONSIDERED:
--	------------------

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 09/856,812	ATTY. DOCKET NO.: L0461.70115US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: September 7, 2001	CONFIRMATION NO.: 3475
			APPLICANT: Lan-Qing Huang et al.	
Sheet		of	GROUP ART UNIT: 1642	EXAMINER: Davis, Minh Tam B.

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/T.D./	C18	TAM, JAMES P. et al., "Incorporation of T and B Epitopes of the Circumsporozoite Protein in a Chemically Defined Synthetic Vaccine Against Malaria," <i>J. Exp. Med.</i> January 1990; 171:299-306.	
	C19	THOMSON, SCOTT A. et al., "Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design," <i>Proc. Natl. Acad. Sci. USA</i> June 1995; 92:5845-5849.	
	C20	TRAVERSARI, CATIA et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E," <i>J. Exp. Med.</i> November 1992; 176:1453-1457.	
	C21	UYTTENHOVE, CATHERINE et al., "The Expression of Mouse Gene P1A in Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a P1A-Encoded Tumor Antigen," <i>Int. J. Cancer</i> 1997; 70:349-356.	
	C22	VAN DEN EYNDE, B. et al., "Presence on a Human Melanoma of Multiple Antigens Recognized by Autologous CTL," <i>Int. J. Cancer</i> 1989; 44:634-640.	
	C23	VAN DER BRUGGEN, PIERRE et al., "Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601*," <i>Eur. J. Immunol.</i> 1994; 24:2134-2140.	
	C24	VAN DER BRUGGEN, P. et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," <i>Science</i> 13 December 1991; 254:1643-1647.	
↓	C25	VAN DEN EYNDE, BENOIT J. et al., "T cell defined tumor antigens," <i>Current Opinion in Immunology</i> 1997; 9:684-693.	

EXAMINER: /Minh Tam Davis/ (11/13/2007)	DATE CONSIDERED:
--	------------------

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]